康恩貝(600572.SH):江西珍視明獲得化粧品生產許可證
格隆匯 2 月 24日丨康恩貝(600572.SH)公佈,近日,公司控股80%的子公司江西珍視明藥業有限公司(“江西珍視明”)收到江西省藥品監督管理局頒發的《化粧品生產許可證》,許可項目:一般液態單元(護膚水類)(含眼部用護膚類)。
江西珍視明此次取得《化粧品生產許可證》,為該公司日後相關護膚產品(含眼部用護膚類產品)的研發生產提供了資質保障,有利於完善該公司健康消費品的研產銷產業鏈建設,加快新產品開發生產,進一步提高該公司在眼健康消費品領域的市場競爭力,助力公司大健康業務戰略的佈局和實施。江西珍視明此次獲得《化粧品生產許可證》短期內不會對公司業績產生重大影響。
江西珍視明眼健康系列產品主要採用自主生產與合同委託生產相結合的生產模式,自2013年開始主要通過天貓、京東等電商平台以B2C模式銷售給消費者,現有眼健康系列產品主要為眼罩、護眼貼和洗眼液。因受國家政策、市場環境、供求關係等因素影響,此次江西珍視明取得《化粧品生產許可證》後續開展化粧品生產,未來的銷售及收入存在不確定性,敬請廣大投資者謹慎決策,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.